Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT
Robert W. Chen, Stephen J. Forman(City Of Hope National Medical Center), Tanya Siddiqi(City Of Hope National Medical Center), Michelle Mott(City of Hope), Firoozeh Sahebi(City Of Hope National Medical Center), John P. Leonard(New York University), Peter Martin(Northwestern University), Tsiporah B. Shore(Cornell University), Young Kim(University of Oklahoma Health Sciences Center), Leslie Popplewell(City Of Hope National Medical Center), Nicole Tsai(City of Hope), Joycelynne Palmer(City of Hope)
Cited by 14
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k